References
- Mills KT, Stefanescu A, He J.
The global epidemiology of hypertension. Nat Rev Nephrol 2020;
16:223-237.
- NCD Risk Factor Collaboration
(NCD-RisC). Worldwide trends in hypertension prevalence and progress
in treatment and control from 1990 to 2019: a pooled analysis of 1201
population-representative studies with 104 million participants.Lancet 2021; 398:957-980.
- Martínez-Rueda AJ,
Olivas-Martínez A, Vega-Vega O, Fonseca-Correa JI, Correa-Rotter R.
New 2017 American College of Cardiology / American Heart Association
High Blood Pressure Guideline. Hypertension 2019; 73: 142-147.
- Chatelanat O, Pechère-Bertschi
A, Ponte B. Sensibilité au sel et hypertension artérielle [Salt
sensitivity and hypertension]. Rev Med Suisse2019;15:1625-1628.
- Di Palo KE, Barone NJ.
Hypertension and Heart Failure: Prevention, Targets, and Treatment.Heart Fail Clin 2020; 16:99-106.
- Cuka E, Simonini M, Lanzani C,
Zagato L, Citterio L, Messaggio E, et al . Inverse salt
sensitivity: an independent risk factor for cardiovascular damage in
essential hypertension. J Hypertens 2022; 40:1504-1512.
- Garfinkle MA. Salt and
essential hypertension: pathophysiology and implications for
treatment. J Am Soc Hypertens 2017; 11:385-391.
- Kuchulakanti PK. ARNI in
cardiovascular disease: current evidence and future perspectives.Future Cardiol 2020; 16:505-515.
- Yancy CW, Jessup M, Bozkurt B,
Butler J, Casey DE Jr, Colvin MM, et al . 2017 ACC/AHA/HFSA
Focused Update of the 2013 ACCF/AHA Guideline for the Management of
Heart Failure: A Report of the American College of Cardiology/American
Heart Association Task Force on Clinical Practice Guidelines and the
Heart Failure Society of America. Circulation 2017;
136:e137-e161.
- Ponikowski P, Voors AA, Anker
SD, Bueno H, Cleland JG, Coats AJ, et al . 2016 ESC Guidelines
for the diagnosis and treatment of acute and chronic heart failure:
The Task Force for the diagnosis and treatment of acute and chronic
heart failure of the European Society of Cardiology (ESC). Developed
with the special contribution of the Heart Failure Association (HFA)
of the ESC. Eur J Heart Fail 2016; 18:891-975.
- Yamamoto K, Rakugi H.
Angiotensin receptor-neprilysin inhibitors: Comprehensive review and
implications in hypertension treatment. Hypertens Res 2021;
44:1239-1250.
- Wang TD, Tan RS, Lee HY, Ihm
SH, Rhee MY, Tomlinson B, et al . Effects of
Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood
Pressures, and NT-proBNP in Salt-Sensitive Hypertension.Hypertension 2017; 69:32-41.
- Williams B, Cockcroft JR, Kario
K, Zappe DH, Brunel PC, Wang Q, et al . Effects of
Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the
Elderly With Systolic Hypertension: The PARAMETER Study.Hypertension 2017; 69:411-420.
- Supasyndh O, Wang J, Hafeez K,
Zhang Y, Zhang J, Rakugi H. Efficacy and Safety of
Sacubitril/Valsartan (LCZ696) Compared With Olmesartan in Elderly
Asian Patients (≥65 Years) With Systolic Hypertension. Am J
Hypertens 2017; 30:1163-1169.
- Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP.
Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of
the angiotensin II receptor and neprilysin: a randomised,
double-blind, placebo-controlled, active comparator study.Lancet 2010; 375:1255-1266.
- Ye L, Wang J, Chen Q, Yang X.
LCZ696, a promising novel agent in treating hypertension (a
meta-analysis of randomized controlled trials). Oncotarget2017; 8:107991-108005.
- Sun J, Xu W, Hua H, Xiao Y,
Chen X, Gao Z, et al . Pharmacodynamic and pharmacokinetic
effects of S086, a novel angiotensin receptor neprilysin inhibitor.Biomed Pharmacother 2020; 129:110410.
- Hu Y, Zhang H, Li X, Mai J,
Yang L, Yan J, et al . A randomized, double-blind,
placebo-controlled, single, and multiple dose-escalation Phase I
clinical trial to investigate the safety, pharmacokinetic, and
pharmacodynamic profiles of oral S086, a novel angiotensin
receptor-neprilysin inhibitor, in healthy Chinese volunteers.Expert Opin Investig Drugs 2021; 8:1-9.
- Curtis MJ, Alexander S, Cirino
G, Docherty JR, George CH, Giembycz MA, et al . Experimental
design and analysis and their reporting II: updated and simplified
guidance for authors and peer reviewers. Br J Pharmacol 2018;
175:987-993.
- Morris CJ, Hastings JA, Boyd K,
Krainski F, Perhonen MA, Scheer
FA, et al . Day/night
variability in blood pressure: influence of posture and physical
activity. Am J Hypertens 2013; 26:822-830.
- Parati G, Staessen JA.
Day-night blood pressure variations: mechanisms, reproducibility and
clinical relevance. J Hypertens 2007; 25:2377-2380.
- Acosta J, Bussi IL, Esquivel M,
Höcht C, Golombek DA, Agostino PV. Circadian modulation of motivation
in mice. Behav Brain Res 2020; 382:112471.
- Tahara Y, Aoyama S, Shibata S.
The mammalian circadian clock and its entrainment by stress and
exercise. J Physiol Sci 2017; 67:1-10.
- Carmichael CY, Wainford RD.
Hypothalamic signaling mechanisms in hypertension. Curr
Hypertens Rep 2015; 17:39.
- Van Liefde I, Vauquelin G.
Sartan-AT1 receptor interactions: in vitro evidence for insurmountable
antagonism and inverse agonism. Mol Cell Endocrinol 2009;
302:237-243.
- Han Y, Ayalasomayajula S, Pan
W, Yang F, Yuan Y, Langenickel T, et al . Pharmacokinetics,
Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After
Single-Dose Administration in Healthy Chinese Subjects. Eur J
Drug Metab Pharmacokinet 2017; 42:109-116.
- Singh JSS, Burrell LM, Cherif
M, Squire IB, Clark AL, Lang CC. Sacubitril/valsartan: beyond
natriuretic peptides. Heart. 2017 Oct;103(20):1569-1577. doi:
10.1136/heartjnl-2017-311295. Epub 2017 Jul 8. PMID: 28689178.
- Campbell HT, Lightfoot BO,
Sklar AH. Four-hour atrial natriuretic peptide infusion in conscious
rats: effects on urinary volume, sodium, and cyclic GMP. Proc
Soc Exp Biol Med 1988; 189:317-324.
- Wong PC, Hart SD, Duncia JV,
Timmermans PB. Nonpeptide angiotensin II receptor antagonists. Studies
with DuP 753 and EXP3174 in dogs. Eur J Pharmacol. 1991 Sep
24;202(3):323-30. doi: 10.1016/0014-2999(91)90274-t. PMID: 1748155.
- Salazar J, Rojas-Quintero J,
Cano C, Pérez JL, Ramírez P, Carrasquero R, et al . Neprilysin:
A Potential Therapeutic Target of Arterial Hypertension? Curr
Cardiol Rev 2020; 16:25-35.
- Tabrizchi R. Omapatrilat.
Bristol-Myers Squibb. Curr Opin Investig Drugs 2001;
2:1414-1422.
- Dzielska-Olczak M.
Omapatrilat–nowy lek dla chorych na nadciśnienie tetnicze i
niewydolność serca [Omapatrilat–new drug for patients with
hypertension and heart failure]. Pol Merkur Lekarski 2005;
19:556-563.
- Kim H, Jang S, Kim IW. Enhanced
Dissolution of Naproxen by Combining Cocrystallization and Eutectic
Formation. Pharmaceutics 2021; 13:618.
- Cysewski P. In silico screening
of dicarboxylic acids for cocrystallization with phenylpiperazine
derivatives based on both cocrystallization propensity and solubility
advantage. J Mol Model 2017; 23:136.